{
"ranked_hypotheses": [
{
"rank": 1,
"title": "TREM2/APOE4-Modulated Metabolic Reprogramming Drives Inflammatory Microglial Priming",
"mechanism": "APOE4 and TREM2 R47H impair microglial metabolic flexibility by disrupting PI3K/AKT signaling and glycolytic adaptation, locking cells into a pro-inflammatory state characterized by glycolysis addiction, mitochondrial dysfunction, and heightened DAMPs responsiveness during prodromal AD.",
"target_gene": "TREM2/APOE",
"confidence_score": 0.78,
"novelty_score": 0.55,
"feasibility_score": 0.72,
"impact_score": 0.75,
"composite_score": 0.72,
"testable_prediction": "Single-cell RNA-seq of TREM2 R47H iPSC-derived microglia exposed to peripheral cytokines will show glycolytic gene upregulation and impaired oxidative phosphorylation gene programs compared to wild-type controls.",
"skeptic_concern": "Metabolic changes may be secondary effects of activation rather than causative drivers of priming."
},
{
"rank": 2,
"title": "DAMPs/PRR Signaling Threshold Lowering Establishes Microglial Inflammatory Memory",
"mechanism": "Chronic peripheral inflammation generates circulating DAMPs (HMGB1, ATP, mtDNA) that continuously engage microglial PRRs (TLR4, TLR9, P2X7R), progressively lowering activation thresholds so that subthreshold Aβ aggregates trigger exaggerated TNFα/IL1β responses in prodromal phases.",
"target_gene": "HMGB1/TLR4/P2X7R",
"confidence_score": 0.70,
"novelty_score": 0.65,
"feasibility_score": 0.65,
"impact_score": 0.72,
"composite_score": 0.69,
"testable_prediction": "Peripheral LPS pretreatment in 5xFAD mice will result in increased HMGB1-TLR4 colocalization in hippocampal microglia and exaggerated cytokine surges upon subthreshold Aβ challenge compared to vehicle-pretreated controls.",
"skeptic_concern": "DAMPs may represent biomarkers of existing pathology rather than causal priming mechanisms."
},
{
"rank": 3,
"title": "PRC2/EZH2 Epigenetic Lock-In Perpetuates Peripheral Inflammation Memory in Microglia",
"mechanism": "Sustained peripheral inflammaging causes NF-κB p65-mediated EZH2 downregulation, depleting repressive H3K27me3 marks at pro-inflammatory gene loci and creating transcriptionally unlocked promoters that mount hypersensitive responses to CNS-derived subthreshold stimuli.",
"target_gene": "EZH2",
"confidence_score": 0.58,
"novelty_score": 0.75,
"feasibility_score": 0.40,
"impact_score": 0.78,
"composite_score": 0.64,
"testable_prediction": "ChIP-seq comparing H3K27me3 enrichment at IL1β, TNFα, and CCL2 promoters in aged APOE4 vs. APOE3 microglia will reveal significant mark depletion correlated with LPS hyperresponsiveness.",
"skeptic_concern": "EZH2 loss may be a consequence of activation rather than its cause, and selective pharmacological restoration of EZH2 in microglia without oncological risk remains technically challenging."
}
],
"consensus_points": [
"Microglial priming represents a critical early mechanism in AD pathophysiology preceding frank pathology",
"Genetic risk factors (APOE4, TREM2 R47H) and peripheral inflammation converge on shared microglial activation pathways",
"The prodromal phase offers a therapeutic window where microglial reprogramming could modify disease trajectory"
],
"dissent_points": [
"Whether microglial metabolic/epigenetic changes are causative drivers of priming or merely epiphenomena of activation state remains unresolved"
],
"debate_summary": "The debate converges on microglial priming as a central early AD mechanism where peripheral inflammation, aging, and genetic risk factors synergistically drive pathological activation states. While the TREM2/APOE-metabolic axis received the highest composite score due to superior experimental tractability and established mechanistic foundations, the epigenetic PRC2/EZH2 hypothesis offers the greatest theoretical novelty despite facing significant pharmacological feasibility concerns. DAMPs/PRR signaling represents a mediating mechanism with moderate support across all perspectives."
}